Press release – For immediate release – 5:45 pm CEST
Half year Median Technologies liquidity contract statement contracted with Louis Capital Markets UK LLP
Under the liquidity contract entrusted by Median Technologies (FR0011049824 – ALMDT FP) to Louis Capital Markets UK LLP, the following resources were listed in the liquidity account as of June 30, 2020:
- 32,518 shares
- €77,124.37 in cash
Transactions during the first half 2020:
| BUY | 114,265 shares | 455,351.48 EUR | 183 transactions |
| SELL | 86,151 titres | 359,264.84 EUR | 259 transactions |
For information, as of May 4th, 2020, when the new liquidity contract was set up, the following resources were listed in the liquidity account:
- 4,404 shares
- €173,829.64 in cash
Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We harness the power of medical images by using the most advanced Artificial Intelligence technologies, to increase the accuracy of diagnosis and treatment of many cancers and other metabolic diseases at their earliest stages and provide insights into novel therapies for patients. Our iCRO solutions for medical image analysis and management in oncology trials and iBiopsy®, our AI-powered software as medical device help biopharmaceutical companies and clinicians to bring new treatments and diagnose patients earlier and more accurately. This is how we are helping to create a healthier world.